InvestorsHub Logo
Followers 1
Posts 50
Boards Moderated 0
Alias Born 11/19/2013

Re: Bristol19 post# 10151

Monday, 07/07/2014 1:58:17 PM

Monday, July 07, 2014 1:58:17 PM

Post# of 140480
I agree with SOME of your comments relative to your previous posts. While there is much territory to be covered by the Titan team, they have committed large quantities of time/treasure to bring this platform from concept to testing.

Decision making within the hospital/physician environment takes into consideration efficacy, safety, outcomes, and cost. If a drug/device/surgical platform is able to show parity relative to a similar modality, than cost and physician confidence will drive utilization. In this instance, the level of disdain for the ISRG approach, coupled with a very real niche marketplace in community hospitals, and ambulatory surgery centers, positions Titan extremely well. Not to mention the hospitals who are going to invest in the alternative.

I don't see the need for multiple Titan units - somewhat defeats the purpose of their approach, don't you think? Surgeons have been driving this development from day 1, MIS is here to stay, its due to physician driven feedback and design.